Physical therapy and adjunctive botulinum toxin type A in the treatment of cervical headache: A double-blind, randomised, placebo-controlled study

被引：0

作者：

Schnider P. ^{[1
]}

Moraru E. ^{[1
]}

Vigl M. ^{[1
]}

Wöber C. ^{[1
]}

Földy D. ^{[1
]}

Maly J. ^{[1
]}

Bittner C. ^{[2
]}

Wessely P. ^{[1
]}

Auff E. ^{[1
]}

机构：

[1] Department of Neurology, Faculty of Medicine, University of Vienna, A-1090 Vienna

[2] Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Vienna, Vienna

来源：

The Journal of Headache and Pain | 2002年 / 3卷 / 2期

关键词：

Botulinum toxin type A; Cervical headache; Physical therapy;

D O I：

10.1007/s101940200024

中图分类号：

学科分类号：

摘要：

We examined the efficacy of physical therapy and adjunctive botulinum toxin type A (BTX-A) injections in the treatment of cervical headache. We performed a double-blind, randomised, placebo-controlled study over a 12-week period in a university clinic outpatients department. A total of 33 patients with cervical headache, diagnosed according to International Headache Society classification were enrolled. All patients received standardized physical therapy over a three-week period. Patients were randomised to receive either BTX-A (Botox) or placebo. The BTX-A group received a total dose of 90 mouse units (mu) BTX-A at six trigger points while the placebo group received saline. Pain characteristics were reported in a headache diary. Tenderness in the neck muscles, the sagittal range of motion and biofeedback measurement were also documented. Both groups showed significant improvement in terms of headache severity (p<0.05), number of headache-free days (p=0.005) and number of headache hours per day (p<0.05). Trends towards an increase in the number of headache-free days and a decrease in headache hours per day were observed in the BTX-A group. No major side effects were observed. Physical measures and BTX-A injections are safe and effective in the treatment of cervical headache.

引用

页码：93 / 99

页数：6

共 18 条

[1]

Jankovic J., Brin M.F., Therapeutic uses of botulinum toxin, N. Engl. J. Med, 324, pp. 1186-1194, (1999)

[2]

Wheeler A.H., Goolkasian P., Gretz S.S., Fanciullo G.J., A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome, Spine, 23, pp. 1662-1667, (1998)

[3]

Cheshire W.P., Abashian S.W., Mann J.D., Botulinum toxin in the treatment of myofascial pain syndrome, Pain, 59, pp. 65-69, (1994)

[4]

Freund B.J., Schwartz M., Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study, Headache, 40, pp. 231-236, (2000)

[5]

Porta M., A comparative trial of botulinum toxin type A and methyl-prednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm, Pain, 85, pp. 101-105, (2000)

[6]

Silberstein O., Matthew N., Saper J., Jenkins S., Botulinum toxin type A as a migraine preventive treatment: For the BOTOX Migraine Clinical Research Group, Headache, 40, pp. 445-450, (2000)

[7]

Smuts J.A., Baker M.K., Smuts H.M., Stassen J.M.R., Rossouw E., Barnard P.W.A., Prophylactic treatment of chronic tension-type headache using botulinum toxin type A, Eur. J. Neurol, 6, SUPPL. 4, pp. 99-102, (1999)

[8]

Hobson D.E., Gladish D.F., Botulinum toxin injection for cervicogenic headache, Headache, 37, pp. 253-255, (1997)

[9]

Relja M., Treatment of tension-type headache by local injection of botulinum toxin, Eur. J. Neurol, 4, (1997)

[10]

Relja M., Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society, Cephalalgia, 8, SUPPL. 7, pp. 1-96, (1998)

← 1 2 →